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Abstract 
Introduction: Despite considerable progress in knowledge, ischaemic stroke is still a disease 
that causes serious clinical problems. A role in its pathogenesis can be attributed to i.a. adipose 
tissue hormones. The aim of this paper is to assess the blood levels of selected adipocytokines 
in patients during the acute phase of ischaemic stroke as compared to healthy persons, and an 
attempt to indicate a correlation between their blood concentrations and the level of stroke 
severity and its outcomes. 
Material and methods: The study included 46 patients with fresh ischaemic stroke (27 
females, 19 males, average age 67.6 years). All patients had a CT scan of the head, their 
neurological condition was assessed using a stroke severity scale, and their blood levels of 
resistin, chemerin, and visfatin were tested. The control group consisted of 32 patients (16 
females, 16 males, average age 64.1 years) who had never suffered cerebrovascular diseases. 
Results: Elevated levels of both resistin and chemerin were found in the group of patients with 
ischaemic stroke (9.17 ± 2.95 ng/mL vs. 6.55 ± 2.01 ng/mL for resistin and 265.0 ± 59.3 ng/mL 
vs. 191.0 ± 43.6 ng/mL for chemerin). It was also found that the blood concentration of 
chemerin was higher in females than in males with stroke. However, no difference was found 
in visfatin blood concentration between the group with ischaemic stroke and the control group 
(1.65 ± 1.09 ng/mL vs. 1.5 ± 1.39 ng/mL). 
Conclusions: Higher resistin and chemerin blood concentrations significantly increase the risk 
of ischaemic stroke. The level of stroke severity at the moment of its occurrence and during its 
course do not depend on the concentrations of adipocytokines under analysis.  
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Introduction 
According to the WHO, strokes, along with cardiovascular diseases and cancer, are the 
leading causes of death for adults globally [1]. In Poland the deaths caused by stroke comprise 
a significant percentage of the total number of deaths [2]. It is estimated that over 60 thousand 
Polish inhabitants have an ischaemic stroke every year [3]. Currently, in Poland more than 
400,000 persons suffer from permanent effects of stroke [2]. 
Over the last two decades, significant progress in treating ischaemic stroke has been 
made. Not only the comprehensive treatment in specialised stroke units but also thrombolytic 
treatment (recombinant tissue plasminogen activator — rt-PA, alteplase), the use of 
acetylsalicylic acid (ASA) within 24 hours of the stroke, and hemicraniectomy in selected cases 
are worth mentioning [4, 5]. 
Another problem is the stroke pathogenesis — it is still not fully explained. Adipose 
tissue is currently perceived not only as energy storage but also as an important endocrine organ 
secreting a number of adipocytokines that can affect the appetite, metabolic, endocrine, and 
immune body functions. Because of their multifunctional character, these substances have been 
a subject of research for many years. The interconnection between adipocytokines and 
ischaemic stroke as well as coronary disease, arterial hypertension, metabolic syndrome, and 
venous thrombosis was reported in many papers [6–8]. 
Resistin is produced by adipose tissue and blood macrophages. Its role is to increase the 
level of blood serum glucose and free fatty acids and inhibit glucose uptake by cells, which can 
increase insulin resistance (IR). Higher resistin levels are observed in obese individuals and 
people with type 2 diabetes [9]. The role of resistin in the pathogenesis of vascular diseases is 
still not fully explained; however, the majority of papers on the subject describe a relationship 
between resistin and the risk of cardiovascular (mainly coronary) incidents. So far, most authors 
emphasise the role of resistin in ischaemic stroke aetiology and prognosis [9–11]. 
Chemerin takes part in adipogenesis, adipose tissue regulation, and infiltrating adipose 
tissue by macrophages. It shows both anti-inflammatory and pro-inflammatory effects, i.e. it 
stimulates the chemotaxis of dendritic cells, macrophages, and natural killer (NK) cells to 
inflammatory foci and reduces the secretion of mediators and pro-inflammatory cytokines, 
including TNF-alpha and IL-6. It has been proven that chemerin affects the sensitivity of 
adipocytes to insulin and increases the insulin-stimulated glucose uptake by adipose tissue [12, 
13].  
Visfatin is produced both by adipocytes and macrophages. It stimulates the 
differentiation of preadipocytes to mature adipocytes and reduces the concentration of blood 
glucose (binding directly to the insulin receptor results in increased glucose uptake) without 
affecting insulinaemia [14]. The role of both chemerin and visfatin in the pathogenesis of 
ischaemic stroke is still not fully explained. 
 
Material and methods 
The study comprised 46 patients hospitalised at a Stroke Unit in the acute phase of 
ischaemic stroke (27 females and 19 males, 29 to 85 years of age, average age 67.6 years). 
Eligibility criteria were: confirmed ischaemic stroke with a neurological deficit lasting more 
than 24 hours, and the possibility of taking a blood sample for testing within 24 hours from the 
occurrence of stroke clinical symptoms. Exclusion criteria: haemorrhagic stroke, subarachnoid 
haemorrhage, brain tumour or any type of cancer, kidney/liver failure, severe infection, injury, 
surgery, myocardial infarction (MI) diagnosed over the last month, thyroid gland diseases 
diagnosed and treated, as well as diabetes in history. 
The control group included 32 patients (16 females and 16 males, 30 to 86 years of age, 
average age 64.1) hospitalised at a neurology ward for back pain syndrome, who had never had 
a cerebral stroke or transient cerebral ischaemia (transient ischaemic attack) and who had not 
suffered any other chronic diseases except for arterial hypertension. 
The Bioethics Committee operating at the Regional Medical Chamber in Łódź (K.B. 
No. –7/17 of 5 April 2017) granted permission to conduct the study. 
Basic laboratory tests were performed for all patients: CBC, lipid profile (total 
cholesterol, LDL, HDL, triglycerides), electrolyte levels (Na, K, Mg, Cl), TSH, fT3, fT4, CRP, 
creatinine, fasting glycaemia, and INR, and body mass index (BMI) was calculated. The 
severity of stroke was assessed in all patients by using the National Institutes of Health Stroke 
Scale (NIHSS) and Barthel Index (BI) for stroke severity (on day 1 and day 9 after the stroke 
onset), as well as the flows in intra- and extracranial arteries by using Doppler ultrasonography 
to detect any stenosis and intima–media (IT) thickness. 
While taking a blood sample for basic biochemical tests (on day 1 after the occurrence 
of stroke symptoms) an additional full blood sample was taken of approx. 20 ml volume. The 
serum obtained after blood centrifugation was frozen at –80ºC. 
After collecting the whole material, the concentrations of selected adipose tissue 
hormones, i.e. resistin, chemerin, visfatin were determined. Tests were performed using 
commercially available immunoassays (BioVendor). 
The database of clinical material was created by using a licensed version of Microsoft 
EXCEL spreadsheet v. 2010. 
Statistical calculations were performed by using licensed statistical software packages. 
Statistica v. 7.1 PL supplied by StatSoft, MedCalc Statistical Software v.14.10.2 and PQStat 
Software v. 1.6.6. During the statistical analysis, a significance level of p < 0.05 was assumed. 
 
Results 
The general characteristics of the study group and the control group did not show any 
significant statistical differences in terms of basic biochemical parameters and BMI. Only 
a higher percentage of patients with elevated fasting glycaemia and elevated CRP level as well 
as reduced potassium levels were found in the group with ischaemic stroke (Tab. I).  
 
Table I. Characteristics of patients with ischaemic stroke and control group 
 Ischaemic 
stroke 
(n = 46) 
Control  
(n = 32) 
p value 
Age (years) 67.6 
(SD ± 12.92) 
64.1  
(SD ± 64.1) 
0.0851 
Total cholesterol 
[mg/dL] 
186  
(SD ± 55.52) 
195.6  
(SD ± 35.77) 
0.2161 
HDL [mg/dL] 50.7  
(SD ± 14.12) 
57.8  
(SD ± 11.28) 
0.0093 
LDL [mg/dL] 118.7 
(SD ± 39.4) 
130.6  
(SD ± 34.48) 
0.1892 
TG [mg/dL] 148.1 
(SD ± 78.81) 
118.7  
(SD ± 63.51) 
0.1042 
Na [mmol/L] 139.3  
(SD ± 3.13) 
139.6  
(SD ± 2.55) 
0.6772 
K [mmol/L] 3.93  
(SD ± 0.45) 
4.22  
(SD ± 0.47) 
0.0078 
Mg [mg/dL] 1.98 
(SD ± 0.25) 
2.02  
(SD ± 0.2) 
0.1793 
Cl [mmol/L] 102.7 
(SD ± 4.25) 
103  
(SD ± 3.2 = 19) 
0.5681 
Creatine [mg/dL] 0.88 
(SD ± 0.28) 
0.76  
(SD ± 0.19) 
0.5681 
TSH [uIU/mL] 1.72 
(SD ± 1.69) 
1.29  
(SD ± 0.94) 
0.4951 
fT3 [pg/dL] 2.68 
(SD ± 0.59) 
2.71  
(SD ± 0.54) 
0.7862 
fT4 [ng/dL] 1.45 
(SD ± 0.4) 
1.29  
(SD ± 0.21) 
0.1425 
Thrombocytes [K/ul] 231 
(SD ± 73) 
234.5  
(SD ± 52.3) 
0.4887 
Leukocytes [K/ul] 8.63 
(SD ± 2.43) 
8.05  
(SD ± 2.55) 
0.2223 
CRP [mg/dL] 0.57 
(SD ± 0.73) 
0.33  
(SD ± 0.53) 
0.0367 
Fasting glycaemia 
[mg/dL] 
107.7 
(SD ± 32.4) 
93.8  
(SD ± 10.7) 
0.0477 
BMI 27.3 
(SD ± 4.5) 
27.4  
(SD ± 4.1) 
0.9615 
HDL — high-density lipoprotein; LDL — low-density lipoprotein; TG — triglycerides; Na — 
sodium; K — potassium; Mg — magnesium; Cl — chlorine; TSH — thyroid stimulating 
hormone; fT3 — triiodothyronine; fT4 — thyroxine; CRP — C-reactive protein; BMI — body 
mass index 
 
The concentration of resistin in the study group ranged from 4.94 to18.10 ng/mL with an 
average value of 9.17 ± 2.95 ng/mL, while in the control group it ranged from 3.28 to 13.23 
ng/mL with an average value of 6.55 ± 2.01 ng/mL. The comparison of resistin concentration 
in both groups showed that in the cerebral stroke group the concentration of this adipocytokine 
was statistically significantly higher than in the control group (p < 0.0001). Logistic regression 
allowed us to ascertain that resistin was a significant risk factor for stroke (Tab. II, III). 
The concentration of chemerin in the study group ranged from 187.2 to 508.2 ng/mL with an 
average value of 265.0 ± 59.3 ng/mL, while in the control group it ranged from 134.1 to 319.1 
ng/mL with an average value of 191.0 ± 43.6 ng/mL. The comparison of chemerin 
concentration between the groups showed that in the cerebral stroke group the concentration of 
this adipocytokine was statistically significantly higher than in the control group (p < 0.0001). 
Logistic regression was used to confirm that chemerin was a significant risk factor for stroke. 
In addition, it was found that the concentration of chemerin was statistically significantly higher 
in females (average 279.4 ± 68.87) than in males (244.6 ± 34.69) in the stroke group (p = 
0.0493) (Tab. II, III). 
The concentration of visfatin in the study group ranged from 0.49 to 5.31 ng/mL with an average 
value of 1.65 ± 1.09 ng/mL, while in the control group it ranged from 0.22 to 6.77ng/mL with 
an average value of 1.5 ± 1.39 ng/mL. No significant statistical difference in visfatin 
concentrations in both groups (Tab. II) was found. 
The study showed no correlation between the concentration of resistin, chemerin, and visfatin 
and the age of the study group. This correlation between the concentrations of adipocytokines 
and BMI was not found either (Tab. IV). 
 
Table II. Resistin, chemerin, and visfatin in patients with ischaemic stroke and in the control 
group 
 Ischaemic 
stroke (n = 46) 
Control 
(n = 32) 
p value 
Resistin [ng/mL] 9.17  
(SD ± 2.95) 
6.55  
(SD ± 2.01) 
< 0.0001 
Chemerin [ng/mL] 265.0  
(SD ± 59.3) 
191.0  
(SD ± 43.6) 
< 0.0001 
Visfatin [ng/mL] 1.65  
(SD ± 1.09) 
1.5  
(SD ± 1.39) 
0.1061 
 
 
Table III. Multifactorial logistic regression 
p < 0.0001; R2Nagelkere = 0.6761 
 Coefficient Standard 
error 
p Odds ratio 95% CI 
Resistin 0.3832 0.1612 0.0174 1.4669 1.0696–2.0119 
Chemerin 0.0443 0.0123 0.0003 1.0453 1.0204–1.0707 
CI — confidence interval 
 
Table IV. Correlations of blood adipocytokines concentrations with body mass index (BMI) 
and age in patients with ischaemic stroke 
 Resistin [ng/mL] Chemerin [ng/mL] Visfatin [ng/mL] 
 R p value R p value R p value 
BMI 0.1829 0.2786 0.060 0.715 –0.0284 0.8696 
Age 0.0688 0.6495 0.0345 0.8200 –0.1077 0.482 
BMI — body mass index 
 
No significant correlation between the concentrations of adipocytokines under analysis and the 
point values in Barthel scale on day 1 and day 9 from stroke and point values in NIH Stroke 
Scale in patients with ischaemic stroke was noticed (Tab. V). 
 
Table V. Correlations of blood adipocytokines concentrations with National Institutes of 
Health Stroke Scale (NIHSS), and Barthel scale in patients with stroke 
 Resistin [ng/mL] Chemerin [ng/mL] Visfatin [ng/mL] 
 R p value R p value R p value 
NIHSS 
scale 
0.1912 0.2031 0.0735 0.6272 0.1015 0.5069 
Barthel 
start 
–0.2506 0.0929 –0.0899 0.5526 –0.0786 0.6079 
Barthel 
end 
–0.1792 0.2334 –0.0526 0.7285 –0.0867 0.5710 
NIHHS scale — scale of National Institutes of Health Stroke Scale; Barthel start — Barthel 
scale evaluation on admission; Barthel end — Barthel scale evaluation on ninth day following 
admission 
 
No correlation between resistin, chemerin, and visfatin concentration and the thickness of 
intima-media complex was noticed, no significant differences in concentration values of 
adipocytokines under analysis were found between patients with and without carotid artery 
stenosis (Tab. VI, VII). 
 
Table VI. Correlations of blood adipocytokines concentrations with intima–media (IM) 
complex 
 IM complex 
 R p value 
Resistin 
[ng/mL] 
–0.0183 0.9094 
Chemerin 
[ng/mL] 
0.0219 0.8921 
Visfatin 
[ng/mL] 
–0.0478 0.7698 
 
 
 
 
 
Table VII. Resistin, chemerin, and visfatin levels in patients with ischaemic stroke with and 
without carotid artery stenosis in carotid Doppler ultrasonography 
 
 Patients without 
stenosis (n = 36) 
Patients with stenosis 
(n = 5) 
p value 
Resistin 
[ng/mL] 
9.8  
(SD ± 2.77) 
9.15  
(SD ± 3.15) 
0.4972 
Chemerin 
[ng/mL] 
243.80  
(SD ± 53.33) 
266.85  
(SD ± 62.48) 
0.4972 
Visfatin 
[ng/mL] 
1.51  
(SD ± 0.79) 
1.71  
(SD ± 1.18) 
1.000 
 
Discussion 
A prevailing majority of publications on the role of adipose tissue hormones in the 
development of vascular diseases deal with leptin and adiponectin, and a smaller number with 
resistin. Only a few papers analysing the possible role of other adipocytokines, i.a chemerin 
and visfatin, in ischaemic stroke pathogenesis have been published so far.  
 
Resistin 
Resistin is one of the best-known adipocytokines. Over the years its blood concentrations have 
been tested, and its role in the pathogenesis of obesity, arterial hypertension, cardiovascular 
diseases, and stroke has been studied [16, 17]. Qian et al. [18] showed a higher concentration 
of this adipocytokine in the blood of obese mice. In studies on human populations it was also 
found that the concentration of resistin often correlated with BMI and was higher in obese 
individuals [19]. However, we did not observe this correlation, not only for resistin but also for 
chemerin and visfatin. 
Reports on the role of resistin in arterial hypertension are contradictory. Some authors 
do not describe such correlations, but a study conducted in China including 1022 patients with 
diabetes showed a positive correlation between systolic blood pressure and the resistin gene 
polymorphism [20]. Bogański et al. [21] also confirm elevated adipocytokine levels in the group 
of patients with arterial hypertension. 
Reports on the role of resistin in the pathogenesis of atherosclerosis are also sometimes 
contradictory. One study observed patients for six years, the tests were performed before and 
after ischaemic stroke or myocardial infarction. A positive correlation between the 
concentration of resistin and the incidence of myocardial infarction was shown; however, the 
same correlation for stroke was not observed. It should be emphasised that in the mentioned 
paper by Weikert et al. [22] the mechanism of stroke was embolic, which can be independent 
of chronic cerebrovascular disease. Another study including a numerous population of 3201 
individuals showed a correlation between elevated resistin levels and the frequency of 
ischaemic strokes, especially those with embolic and lacunar background. In this case a similar 
correlation was not shown for acute coronary syndromes and haemorrhagic strokes [23]. 
Perovic E et al. [24] also confirmed the presence of higher resistin concentrations in patients 
with ischaemic stroke. Our study showed a significantly higher concentration of this 
adipocytokine in the group of patients with ischaemic stroke as compared to the control group. 
In addition, we found that resistin was an independent risk factor for ischaemic stroke; however, 
its blood concentration did not show any correlation with BMI (probably because patients under 
our analysis did not differ much in terms of body mass).  
Despite the fact that we did not find any correlation of the intima–media (IM) complex 
thickness and the presence of carotid stenosis with resistin blood level, it should be emphasised 
that there are reports describing this correlation not only in patients with past ischaemic cerebral 
stroke but also in asymptomatic patients with unstable atherosclerotic plaque [25]. 
 
Chemerin 
Chemerin is a pro-inflammatory adipokine, the amount of which in the blood is 
correlated with the inflammatory condition and the presence of metabolic syndrome [26]. 
Although knowledge on its pathogenetic role in the development of atherosclerosis is inferior 
to that of other adipocytokines, there are papers available in the literature that confirm the 
positive and negative correlation between chemerin blood concentration and the incidence of 
coronary artery disease [27, 28]. 
Information on patients with cerebral ischaemia is especially sparse. Analysis performed 
by Zoe et al. [29] to assess the correlation between the level of chemerin and ischaemic stroke 
and the occurrence of carotid atherosclerosis shows that chemerin detected in serum can be an 
independent risk factor for ischaemic stroke. The results of our study confirm this observation 
– the concentration of chemerin was significantly higher in patients with ischaemic stroke, 
especially (which is interesting) in females. Existing reports on the correlation between 
chemerin levels and the incidence of unstable atherosclerotic plaque are contradictory. A study 
on the Chinese population showed that chemerin was an independent risk factor for unstable 
carotid atherosclerotic plaques (p < 0.05). On the other hand, there are also studies that 
contradict this. Our study does not show any correlation between chemerin blood level and the 
thickness of IM complex as well as the differences in chemerin concentration in patients with 
and without carotid stenosis. 
 
Visfatin 
The biological role of visfatin consists of differentiation of preadipocytes from 
adipocytes and a strong pro-inflammatory effect induced by activating leukocytes as well as 
stimulating the production of pro-inflammatory cytokines. By binding to insulin receptor, 
visfatin has a hypoglycaemic effect [31]. 
Visfatin has been described as a prognostic factor for death in cardiovascular diseases. 
Its high level was noticed in patients with acute myocardial infarction and obese patients with 
metabolic syndrome [32, 33]. In the past there were also studies and papers describing the role 
of visfatin in acute ischaemic stroke. The majority of papers showed that its blood levels in 
patients with ischaemic cerebral stroke were elevated [34, 35]. Our observations do not confirm 
this correlation. However, it should be emphasised that the groups were uniform in terms of 
BMI. 
Kadoglou et al. [35], in contrast to us, described higher visfatin serum levels in patients 
with acute ischaemic stroke and carotid stenosis (> 50%). Studies conducted by other authors 
show that high blood visfatin levels seem to be strongly correlated with the presence and 
intensity of atherosclerotic lesions in peripheral blood vessels [36]. 
 
Adipocytokines vs. clinical course of a stroke 
In literature there are only isolated reports on the mutual correlation between the 
concentrations of some adipocytokines and the course of a stroke. Studies show a positive 
correlation between the adiponectin concentration and the severity of a stroke, but some studies 
do not confirm this, and may even contradict it [37, 38]. 
Efstathiou SP et al. [39] showed a worse course of ischaemic stroke and a higher death 
rate in patients with high resistin blood level, which was not confirmed in studies conducted by 
Bienek et al. [25, 29, 38]. Our study did not confirm this correlation either. Currently there are 
no similar studies for chemerin and visfatin available in the literature. Our analysis does not 
confirm the correlation between the course of stroke and the level of chemerin and visfatin in 
blood. However, it seems that this assessment requires a study covering a considerably larger 
population. 
 
Conclusions 
The role of adipose tissue hormones in ischaemic stroke is relatively poorly recognised. 
There are only a few publications available that show contradictory results, and usually refer to 
relatively small groups of patients. 
The higher level of resistin and chemerin in the blood of patients with ischaemic stroke 
observed in our study are partially convergent with the studies conducted by other authors, 
which leads us to suspect that there is a pathogenetic connection between them and the risk 
factor for ischaemic stroke.  
By contrast, the analysis of visfatin did not confirm its higher concentration in patients 
with ischaemic stroke, which was unexpected. 
The lack of correlation between the concentrations of the adipocytokines under analysis 
(especially resistin) and BMI is also surprising; however, it should be noted that the patients 
under analysis were uniform in terms of their body mass, and in general they were not obese. 
No correlation between the levels of resistin, chemerin, and visfatin and the severity of stroke 
at the moment of its occurrence and its course was found. 
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